Lenalidomide attenuates post-inflammation pulmonary fibrosis through blocking NF-κB signaling pathway

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice Guideline

Ganesh Raghu, Bram Rochwerg, Yuan Zhang et al. · American Journal of Respiratory and Critical Care Medicine · 2015 · 1.9K citations

Medicine, Clinical Sciences, Internal Medicine +11

Simple method of estimating severity of pulmonary fibrosis on a numerical scale.

T Ashcroft, Judy M. Simpson, V. Timbrell · Journal of Clinical Pathology · 1988 · 1.7K citations

Medicine, Pathobiology, Pathology +15

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

Alan F. List, Gordon W. Dewald, John M. Bennett et al. · New England Journal of Medicine · 2006 · 1.3K citations

Medicine, Hematology, Pharmacology +17

An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis

Gísli Jenkins, Bethany B. Moore, Rachel C. Chambers et al. · American Journal of Respiratory Cell and Molecular Biology · 2017 · 431 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +14

Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro

Keith Dredge, Rebecca Horsfall, Simon P. Robinson et al. · Microvascular Research · 2005 · 268 citations

Medicine, Oncology, Pharmacology +13